Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis
- PMID: 31229669
- DOI: 10.1016/j.ijantimicag.2019.06.016
Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis
Abstract
Effective antibiotic dosing is vital for therapeutic success in critically ill patients. This work aimed to develop an algorithm to identify appropriate meropenem dosing in critically ill patients. Population pharmacokinetic (PK) modelling was performed in NONMEM®7.3 based on densely sampled meropenem serum samples (npatients = 48; nsamples = 1376) and included a systematic analysis of 27 pre-selected covariates to identify factors influencing meropenem exposure. Using Monte Carlo simulations newly considering the uncertainty of PK parameter estimates, standard meropenem dosing was evaluated with respect to attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target and was compared with alternative infusion regimens (short-term, prolonged, continuous; daily dose, 2000-6000 mg). Subsequently, a dosing algorithm was developed to identify appropriate dosing regimens. The two-compartment population PK model included three factors influencing meropenem pharmacokinetics: the Cockcroft-Gault creatinine clearance (CLCRCG) on meropenem clearance; and body weight and albumin on the central and peripheral volume of distribution, respectively; of these, only CLCRCG was identified as a vital influencing factor on PK/PD target attainment. A three-level dosing algorithm was developed (considering PK parameter uncertainty), suggesting dosing regimens depending on renal function and the level (L) of knowledge about the infecting pathogen (L1, pathogen unknown; L2, pathogen known; L3(-MIC), pathogen and susceptibility known; L3(+MIC), MIC known). Whereas patients with higher CLCRCG and lower pathogen susceptibility required mainly intensified dosing regimens, lower than standard doses appeared sufficient for highly susceptible pathogens. In conclusion, a versatile meropenem dosing algorithm for critically ill patients is proposed, indicating appropriate dosing regimens based on patient- and pathogen-specific information.
Keywords: Dosing algorithm; Intensive care; Pharmacokinetics/pharmacodynamics; Renal function; β-Lactams.
Copyright © 2019. Published by Elsevier B.V.
Similar articles
-
Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):695-705. doi: 10.1007/s13318-021-00709-w. Epub 2021 Aug 17. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34403127
-
Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.J Antimicrob Chemother. 2018 May 1;73(5):1330-1339. doi: 10.1093/jac/dkx526. J Antimicrob Chemother. 2018. PMID: 29425283
-
Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Crit Care. 2017 Oct 21;21(1):263. doi: 10.1186/s13054-017-1829-4. Crit Care. 2017. PMID: 29058601 Free PMC article. Clinical Trial.
-
Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.Curr Drug Metab. 2023;24(1):5-15. doi: 10.2174/1389200224666230325121729. Curr Drug Metab. 2023. PMID: 36974414 Review.
-
Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.Blood Purif. 2023;52(6):503-515. doi: 10.1159/000529694. Epub 2023 May 5. Blood Purif. 2023. PMID: 37231811
Cited by
-
The Role of Non-Enzymatic Degradation of Meropenem-Insights from the Bottle to the Body.Antibiotics (Basel). 2021 Jun 14;10(6):715. doi: 10.3390/antibiotics10060715. Antibiotics (Basel). 2021. PMID: 34198482 Free PMC article.
-
Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0032122. doi: 10.1128/aac.00321-22. Epub 2022 Oct 5. Antimicrob Agents Chemother. 2022. PMID: 36197095 Free PMC article.
-
In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae.Clin Microbiol Infect. 2020 Sep;26(9):1256.e1-1256.e8. doi: 10.1016/j.cmi.2020.04.034. Epub 2020 May 5. Clin Microbiol Infect. 2020. PMID: 32387437 Free PMC article.
-
Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study.PLoS One. 2024 Dec 23;19(12):e0313764. doi: 10.1371/journal.pone.0313764. eCollection 2024. PLoS One. 2024. PMID: 39715157 Free PMC article.
-
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study.Infection. 2025 Apr 25. doi: 10.1007/s15010-025-02504-0. Online ahead of print. Infection. 2025. PMID: 40279026
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical